Melitracen

Summary

Melitracen (CHEMBL110094) is a phase-3 clinical-stage small molecule (ATC N06AA14); indicated across 1 condition including depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N06AA14
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 291.4 Da · C21H25N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL110094
Name	Melitracen
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25382
ATC	N06AA14
Molecular formula	C21H25N
Molecular weight	291.4
InChIKey	GWWLWDURRGNSRS-UHFFFAOYSA-N

SMILES: CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C

IUPAC name: 3-(10,10-dimethylanthracen-9-ylidene)-N,N-dimethylpropan-1-amine

Also known as: Adelax, Melitracen, Melitracene, Melitraceno, SID50125798, US8629135, SW-14, MELITRACEN, melitracen

Parent form; salt/anhydrous children: CHEMBL2107109

Patent coverage: 774 distinct patent families (3,127 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,121 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 26 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	7.43	AC50	36.9	nM	CHEMBL_ACT_25211984
CHRM1	6.89	AC50	128.5	nM	CHEMBL_ACT_25134923
SLC6A4	6.62	AC50	240	nM	CHEMBL_ACT_25149827
CHRM2	6.6	AC50	250	nM	CHEMBL_ACT_25213241
CHRM3	6.42	AC50	380	nM	CHEMBL_ACT_25136189
ADRA1A	6.2	AC50	630	nM	CHEMBL_ACT_25217707
SLC6A2	5.98	AC50	1049	nM	CHEMBL_ACT_25144491
DRD3	5.72	AC50	1889	nM	CHEMBL_ACT_25193012
KCNH2	5.38	AC50	4130	nM	CHEMBL_ACT_25117080
HTR3A	5.36	AC50	4400	nM	CHEMBL_ACT_25148609
HTR2B	5.36	AC50	4336	nM	CHEMBL_ACT_25227032
DRD1	5.35	AC50	4500	nM	CHEMBL_ACT_25181211
HTR2A	5.35	AC50	4500	nM	CHEMBL_ACT_25225838
ADRB1	5.28	AC50	5200	nM	CHEMBL_ACT_25121268
DRD2	5.27	AC50	5400	nM	CHEMBL_ACT_25139810
HTR2C	5.24	AC50	5800	nM	CHEMBL_ACT_25131294
ADRA2A	5.17	AC50	6700	nM	CHEMBL_ACT_25219401
ADRA2C	5.01	AC50	9675	nM	CHEMBL_ACT_25147349

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	3	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04970667	PHASE4	COMPLETED	Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder
NCT03205228	PHASE3	COMPLETED	Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
NCT03472651	PHASE1	COMPLETED	Bioequivalence Study to Compare Two Formulations of Deanxit®
NCT06756139	Not specified	RECRUITING	Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).